Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Shen J, Goodkin ML, Tong W, Attar M. Clin Ophthalmol. 2017;11:1761–1767.On page 1765, Clinical correlation with evidence for use of bimatoprost twice daily in humans section, second column, last line, “−5.4 to −5.6 mm Hg” should have read “...
Guardado en:
Autores principales: | Shen J, Goodkin ML, Tong W, Attar M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f26af62ff30e45c68a26c5003e44a6dd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017) -
Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013) -
Once and Twice
por: Richard S. Kayne
Publicado: (2015) -
Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017) -
Efficacy of twice-daily vs once-daily sessions of repetitive transcranial magnetic stimulation in the treatment of major depressive disorder: a retrospective study
por: Modirrousta M, et al.
Publicado: (2018)